What Have We Learned from the Shortening of Treatment for Drug-sensitive TB?

Date:

November 20, 2014 (All Day)

Dr. Richard Chaisson and Dr. Eric Nuermberger talk about what has been learned from recent phase 2 and phase 3 trials of shortening the treatment for drug-sensitive tuberculosis. 

Video/Audio/Slides

Audio-only/Slides

Projects

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More

A Blueprint for Success: Understanding the...

We are using a combination of statistical analysis and transmission modeling, in collaboration with the NYC Dept of Health &...

Read More

TBM-KIDS (Malawi)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More